Higher expression of pseudouridine synthase 7 promotes non-small cell lung cancer progression and suggests a poor prognosis

Abstract

Background Lung cancer is currently the second most common cancer, and non-small cell lung cancer accounts for about 85% of cases. NSCLC has not been studied for pseudouridine synthase 7 (PUS), a member of the PUS family that is associated with cancer development. Here, we focused on the role and clinical significance of PUS7 in non-small cell lung cancer. Aim To explore the role of PUS7 in NSCLC and its clinical significance. Methods We downloaded datasets from the TCGA database and CPTAC database. In normal bronchial epithelial cells as well as NSCLC cell lines, RT-PCR and Western blot were used to quantify PUS7 expression. The role of PUS7 in NSCLC has been investigated by CCK8, migration assay, migration assay, and flow cytometry. PUS7 expression in tumor tissues was detected by immunohistochemical staining, and we evaluated the influence of PUS7 expression on the prognosis of NSCLC patients after surgery using Cox regression analysis, both univariate and multivariate. Results NSCLC cell lines and tissues expressed high levels of PUS7, and PUS7 was found to influence the proliferation, migration, and invasion of cancer cells without affecting their apoptosis. There was a worse prognosis for NSCLC patients who have higher PUS7 expression, suggesting that PUS7 was an independent indicator of prognosis (P = .05).

5-Fluorouracil Treatment Represses Pseudouridine-Containing Small RNA Export into Extracellular Vesicles

“…Consistent with differential activity among pseudouridine synthases, chemotherapeutic resistance to 5-FU is often associated with increased expression of one of more pseudouridine synthases (Jin et al 2022). In hepatocellular carcinoma and colorectal cancer, higher expression of pseudouridine synthases (PUS1, PUS7, PusL1, RPUSD3, DKC1, PUS7L, PUS10, and RPUSD1) correlates with poor prognosis (Jin et al 2022;Liang et al 2022;Zhang et al 2023). Likewise, overexpression of the Dyskerin pseudouridine synthase that acts on rRNA (DKC1) predicts poor prognosis in breast cancer, while knockdown of DKC1 and Mek1/2 restricts colorectal cancer cell growth (Elsharawy et al 2020;Kan et al 2021).…”

Comprehensive analysis to identify PUS7 as a prognostic biomarker from pan-cancer analysis to osteosarcoma validation

“…Du et al also discovered PUS7 overexpression accelerates colon cancer cell proliferation and invasion via PI3K/AKT/mTOR Signaling Pathway [ 13 ]. PUS7 has been proven to be a valid biomarker for lung cancer diagnosis in recent research [ 14 ]. Nonetheless, systematic research on PUS7 function in various malignancies remains lacking.…”